Moteur de recherche d’entreprises européennes
Financement britannique (364 799 £) : Stratégie antipersistante de phagothérapie Ukri 01/04/2025 Recherche et innovation du Royaume-Uni, Royaume Uni
Vue d’ensemble
Texte
Stratégie antipersistante de phagothérapie
| Abstract | Klebsiella pneumoniae and Acinetobacter baumannii are recognized as critical pathogens, while Pseudomonas aeruginosa is considered a high risk pathogen, because of resistance to multiple antibiotics and emerging therapies. The use of viruses of bacteria, called (bacterio)phages, to kill these pathogens is a promising strategy starting to be implemented in multiple countries across the world. Despite this promise, certain chronic infections still harbour bacterial persister cells, even after phage treatment. To address this challenge, the PHAGES-AntiPERS consortium, comprising experts from diverse fields such as medicine, microbiology, and bioinformatics, is dedicated to pioneering innovative strategies to tackle infections. The consortium aims to combat the development of persister cells in chronic and biofilm-associated infections treated with phages and anti-persister treatments. The success of PHAGES-AntiPERS relies on establishing a reference database and biobank of strains from the bacterial species prone to develop persistent infections in humans (K. pneumoniae, A. baumannii, P. aeruginosa). We are also building an AntiPERS Phage Bank tailored to target persister cells, thus laying the groundwork for innovative and effective treatments against persistent infections. Our goal is to devise and verify "anti-persisters proof of concept strategies" by combining antimicrobial agents like antibiotics, strictly lytic phages, phage-derived enzymes, and a variety of previously identified anti-persister compounds. We will investigate the eradication of persister bacterial cells both in laboratory settings and in living organisms, assessing the phenotypic and genomic factors underlying anti-persister activity at both phage and bacterial levels. |
| Category | Research Grant |
| Reference | UKRI882 |
| Status | Active |
| Funded period start | 01/04/2025 |
| Funded period end | 01/04/2028 |
| Funded value | £364 799,00 |
| Source | https://gtr.ukri.org/projects?ref=UKRI882 |
Participating Organisations
| QUADRAM INSTITUTE BIOSCIENCE | |
| Hadassah Medical Center | |
| University of Wroclaw | |
| Koninklijke Militaire School, Laboratory for Molecular and Cellular Technology | |
| Instituto de Investigación Biomédica de A Coruña | |
| Instituto de Salud Carlos III |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Quadram Institute Bioscience, Norwich, Royaume Uni.